摘要
目的探讨尤瑞克林治疗急性脑梗死的临床疗效及安全性。方法急性脑梗死患者200例分为对照组和治疗组,每组各100例,两组予相同的基础治疗,但治疗组加用尤瑞克林0.15PNA单位静脉滴注,每日1次,连用7～14d,同时使用抗血小板药物或抗凝药物进行病因治疗及神经康复治疗,于治疗前后评定患者神经功能缺损程度、日常生活活动能力、伤残或严重程度,并记录不良反应事件。结果治疗后两组患者的神经功能缺损、日常生活活动能力、伤残或严重程度评分均有改善,与治疗前相比差异具有统计学意义(P<O.05);治疗组改善程度更明显,与对照组相比差异具有统计学意义(P<0.01);治疗组较对照组不良反应无明显增加。结论尤瑞克林治疗急性脑梗死安全、有效,值得临床进一步研究探讨。
Objective To investigate the efficacy and safety of Urinary Kallidinogenase in the treatment of acute cerebral infarction（ACI）. Methods Two hundred patients with ACI were randomly divided into the control group and treatment group. The two group patients were all given a basic therapy, but the patients in the treatment group were given the extra treatment with Kallidinogenase injection for seven to fourteen days. They were all given etiological treatment and neurological rehabilitation. All patients were evaluated by the National Institute of Health Stroke scale（NIHSS）, Activity of Daily Living Scale（ADL） and the modified Rankin scale（mRS） before the therapy and after the therapy. Results The improvement in NIHSS, ADL and mRS scores of these patients was significant after treatment, and the treatment group has a significant improvment than the control group. In our study, there was not different between the two groups in the side-effect of Urinary Kallidinogenase. Conclusion Urinary Kallidinogenase showed a relatively confirmative effect on improving cerebral functions and activities of daily living in patients with ACI.
出处
《中国卒中杂志》
2009年第10期817-820,共4页
Chinese Journal of Stroke
关键词
尤瑞克林
脑梗死
治疗结果
Urinary kallidinogenase
Cerebral infarction
Treatment outcome
